The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | Evaluating the prognostic and predictive roles of MMR/MSI status in colon cancer
Alberto Puccini, MD, Humanitas Research Hospital, Rozzano, Italy, comments on the clinical integration of MMR and MSI status in colon cancer management, highlighting its multifaceted role as a biomarker for chemotherapy resistance in the adjuvant setting, a diagnostic marker for Lynch syndrome, and a predictive factor for immunotherapy benefit. MSI status is the only biomarker currently ready for integration with TNM staging, while other potential biomarkers such as circulating tumor DNA (ctDNA) remain insufficiently validated for clinical implementation. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Read more...
Related Videos
